REAL SCIENCE. REAL POSSIBILITIES.An experimental peptide most often associated with sleep, relaxation and the body's response to stress. Human findings are limited and mixed.
DSIP's name makes it sound established, yet sleep findings have been inconsistent. Its best value today is as an unresolved research question rather than a proven sleep treatment.
These cards show what DSIP is best known for and where the interest comes from. When you want the detail, open Research for the studies or Evidence for a quick view of how strong the support is.
The main reasons this compound attracts attention. The Research and Evidence sections give you the deeper scientific picture.
Older trials investigated whether DSIP could normalise disturbed sleep.
Small studies reported some delayed or night-specific effects rather than a clear, immediate sedative action.
Researchers measured EEG stages and 24-hour sleep patterns.
Results varied across timing, population and protocol, with no robust modern efficacy programme.
DSIP has also been studied beyond sleep in neuroendocrine and stress models.
Most stress-protection findings are experimental and do not establish a clinical benefit.
Users hope that better sleep will improve daytime energy and wellbeing.
No strong trial evidence shows durable improvements in daytime function from DSIP treatment.
DSIP was tested in people, but the studies are small, old and inconsistent. Modern bedtime protocols therefore sit well beyond the monitored intravenous sleep-lab evidence.
Nine-amino-acid sleep research candidate
→EEG, latency and sleep-efficiency measures
→Small and variable human findings
→No contemporary confirmatory treatment programme
DSIP has direct human sleep research, but its memorable name is more definitive than the results. Small monitored studies found variable changes in latency, efficiency and sleep structure without creating a reliable insomnia treatment.
Older studies examined latency, awakenings and sleep efficiency rather than simply asking whether DSIP was sedating.
EEG-stage and 24-hour sleep research produced timing- and protocol-dependent findings.
The 1992 double-blind study suggested weak benefit in 16 people and explicitly cautioned about incidental effects.
Contemporary intranasal or subcutaneous use has no confirmatory dose-finding or efficacy programme.
16 people with chronic insomnia
Human volunteers in intermediate-term administration research
Several small human sleep studies exist, mainly from the 1980s and early 1990s.
Results are inconsistent and have not established DSIP as an insomnia treatment.
Short studies provide limited tolerability information; long-term safety is undefined.
Animal and neuroendocrine studies support multiple possible actions but no settled receptor mechanism.
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Small 1980s–1990s studies with variable findings
Multiple neuroendocrine ideas; no settled receptor story
Route, dose-response, daytime outcomes and long-term safety
A measured biological response can be valuable evidence without establishing a self-administered protocol or a durable treatment benefit.
Sleep depth, fewer awakenings and recovery—mapped against small historic sleep-laboratory studies and a major modern-validation gap.
Community goals · historic human data · modern trial gapDSIP attracts people who want deeper sleep, fewer awakenings and better recovery. Its name and anecdotes are more convincing than the small, inconsistent clinical record.
Experiences can reveal recurring goals, perceived changes and practical questions that formal studies may not yet address. They can suggest what deserves investigation, but cannot isolate the effect of one compound from rehabilitation, time or other changes.
Human and preclinical research helps test whether an idea is biologically plausible, whether it appears in people and how confidently the result can be separated from chance, bias or other parts of recovery.
Users often describe vivid changes in perceived sleep depth.
Small sleep-lab studies reported variable and sometimes delayed effects.
EEG and neuroendocrine models suggest sleep-related activity, but mechanism is unresolved.
Direct human research exists, but does not establish reliable efficacy.
The name suggests a direct sleep-inducing effect.
Historic studies did not consistently behave like a conventional immediate hypnotic.
Animal results vary by species, route and timing.
The label 'sleep-inducing' overstates the consistency of the evidence.
Some users discuss calmer nights and better physical recovery.
Robust daytime-function or stress-outcome trials are lacking.
Stress-response and mitochondrial findings have been reported in animal studies.
An experimental extension beyond the already uncertain sleep evidence.
Modern anecdotes usually describe use near bedtime, despite historic trials dosing in the afternoon.
The 1992 insomnia study used monitored IV dosing before three laboratory nights, not a retail nasal or subcutaneous course.
Route and timing can alter exposure and cannot be inferred from animal sleep models.
The community pattern is recognisable but not clinically validated.
Community reports can surface patterns worth exploring. Controlled human research is what tests whether those patterns are reliable, clinically meaningful and attributable toDSIP, while the available studies show how far that question has already been answered.
Compare published study protocols with the patterns people discuss in the community. The two are intentionally kept separate so an anecdotal routine is never mistaken for clinical guidance.
This is a recurring modern community description. The published insomnia study used 25 nmol/kg intravenously in the afternoon under laboratory monitoring.
Anecdotal starting amount
Optional community-described step-up
Upper end of recurring descriptions
No validated maintenance interval
The small 1992 study administered 25 nmol/kg IV before three laboratory nights. Nasal and subcutaneous absorption have not been mapped against that protocol.
The source shows what has actually been studied. It does not validate the community example above or turn it into guidance.
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
Historic intravenous research protocols do not establish a modern intranasal or injected DSIP treatment schedule.
16 people with chronic insomnia
Published study structure, shown as data — not a personal dosing schedule.
A small historic research protocol; not a validated clinical or community dosing schedule.
Community descriptions often begin around 100 mcg near bedtime; 200–300 mcg is also discussed. This is not derived from a validated modern human protocol.
A brief 10–14-night trial window is commonly described, sometimes with intermittent use rather than nightly continuation.
No validated step-up, continuous-use, tolerance-management or break schedule exists.
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
DSIP + Epitalon
DSIP + Behavioural sleep programme
DSIP + Selank
Historic human studies are small and inconsistent; modern bedtime use lacks a validated route or schedule.
Epitalon is discussed around circadian biology, while CBT-I and sleep-disorder care have separate established roles.
Explored around sleep, circadian rhythm and recovery.
No controlled human evidence for the combination.Communities often combine peptide use with sleep-hygiene changes.
Behavioural changes confound anecdotes; CBT-I has a separate established evidence base.Discussed around calmer nights, stress reduction and sleep continuity.
No controlled trial establishes efficacy, sedation risk or an appropriate combined schedule.Insomnia, sleep apnoea, circadian delay and medication effects require different assessment.
Sedating combinations can worsen impairment or obscure an untreated sleep disorder.
Daytime alertness and functioning matter more than a single night of perceived depth.
DSIP is not supported only by animal work; objective sleep measures were collected in small monitored cohorts.
Findings were weak or inconsistent and did not establish a dependable sedative or insomnia treatment.
Nasal and subcutaneous exposure, endocrine effects, interactions and repeated-course safety are poorly characterised.
The summary above reflects the human or preclinical evidence currently represented on this profile.
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Sleep apnoea, restless legs, circadian disorders, depression and medication effects can all present as poor sleep.
Alcohol, hypnotics, opioids and other sedating agents can increase impairment even when DSIP interaction data are absent.
Driving impairment, confusion, unusual mood change or excessive daytime sleepiness requires review.
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
DSIP is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.
